- 著者
- Makoto Hirata Yoichiro Kamatani Akiko Nagai Yutaka Kiyohara Toshiharu Ninomiya Akiko Tamakoshi Zentaro Yamagata Michiaki Kubo Kaori Muto Taisei Mushiroda Yoshinori Murakami Koichiro Yuji Yoichi Furukawa Hitoshi Zembutsu Toshihiro Tanaka Yozo Ohnishi Yusuke Nakamura BioBank Japan Cooperative Hospital Group Koichi Matsuda
- 出版者
- 日本疫学会
- 雑誌
- Journal of Epidemiology (ISSN:09175040)
- 巻号頁・発行日
- vol.27, no.Supplement_III, pp.S9-S21, 2017 (Released:2017-04-14)
- 参考文献数
- 33
- 被引用文献数
- 116
Background: To implement personalized medicine, we established a large-scale patient cohort, BioBank Japan, in 2003. BioBank Japan contains DNA, serum, and clinical information derived from approximately 200,000 patients with 47 diseases. Serum and clinical information were collected annually until 2012.Methods: We analyzed clinical information of participants at enrollment, including age, sex, body mass index, hypertension, and smoking and drinking status, across 47 diseases, and compared the results with the Japanese database on Patient Survey and National Health and Nutrition Survey. We conducted multivariate logistic regression analysis, adjusting for sex and age, to assess the association between family history and disease development.Results: Distribution of age at enrollment reflected the typical age of disease onset. Analysis of the clinical information revealed strong associations between smoking and chronic obstructive pulmonary disease, drinking and esophageal cancer, high body mass index and metabolic disease, and hypertension and cardiovascular disease. Logistic regression analysis showed that individuals with a family history of keloid exhibited a higher odds ratio than those without a family history, highlighting the strong impact of host genetic factor(s) on disease onset.Conclusions: Cross-sectional analysis of the clinical information of participants at enrollment revealed characteristics of the present cohort. Analysis of family history revealed the impact of host genetic factors on each disease. BioBank Japan, by publicly distributing DNA, serum, and clinical information, could be a fundamental infrastructure for the implementation of personalized medicine.